Sanal S M, Flickinger F W, Caudell M J, Sherry R M
Department of Medicine, Medical College of Georgia, Augusta 30912-3125.
J Clin Oncol. 1994 Jul;12(7):1415-21. doi: 10.1200/JCO.1994.12.7.1415.
To evaluate the value of magnetic resonance imaging (MRI) in detecting bone marrow metastases in patients with breast cancer.
Twenty-three patients with breast cancer in various stages (stage IV, 11; stage III, five; stage II, seven) were evaluated for bone marrow involvement. MRIs of marrow from lumbar spine, pelvis, and proximal femora were obtained with a 1.5-Tesla unit. All patients underwent bilateral bone marrow aspirations and biopsies for histologic evaluation and immunostaining with monoclonal antibody (MoAB) against low-molecular weight cytokeratin (CAM 5.2). Marrow MRI findings were compared with technetium 99m bone scans. Patients with stage II or III disease were monitored for clinical outcome. Possible correlation of MRI findings with serum alkaline phosphatase level was explored.
Fourteen of 23 patients showed MRI abnormalities suggestive of metastatic marrow disease (stage IV, nine; stage III, two; stage II, three). In six patients with abnormal MRIs, histology and MoAB immunostaining confirmed marrow involvement (stage IV, five; stage III, zero; stage II, one). In the other eight patients with MRI abnormalities, neither of these methods confirmed the presence of marrow metastasis. Four of five operable breast cancer (stage II-III) patients with an abnormal initial MRI showed additional abnormalities on follow-up examination and developed metastatic disease within 5 to 18 months demonstrable by conventional clinical methods. Conversely, none of the operable patients with negative MRIs developed recurrent disease at 3 to 16 months (Student's t test, P = .01). Nine patients with a normal MRI had no evidence of marrow involvement with histologic or MoAB immunostaining (stage IV, two; stage III, two; stage II, five). Of 14 patients with abnormal MRIs, bone scans were normal in seven and failed to show corresponding abnormalities in six. Elevated serum alkaline phosphatase levels showed a direct relationship with abnormal bone scans indicating extensive bony involvement, but failed to correlate with positive marrow MRIs.
MRI is a promising new technique to detect occult marrow involvement in breast cancer patients. There is a good correlation between abnormal marrow MRI and early development of clinical metastatic disease in patients with stage II to III disease.
评估磁共振成像(MRI)在检测乳腺癌患者骨髓转移中的价值。
对23例处于不同分期(IV期11例;III期5例;II期7例)的乳腺癌患者进行骨髓受累情况评估。使用1.5特斯拉设备获取腰椎、骨盆及股骨近端骨髓的MRI图像。所有患者均接受双侧骨髓穿刺及活检,进行组织学评估及用抗低分子量细胞角蛋白(CAM 5.2)的单克隆抗体(MoAB)进行免疫染色。将骨髓MRI检查结果与锝99m骨扫描结果进行比较。对II期或III期疾病患者进行临床结局监测。探讨MRI检查结果与血清碱性磷酸酶水平之间可能存在的相关性。
23例患者中有14例MRI表现异常,提示存在骨髓转移性疾病(IV期9例;III期2例;II期3例)。在6例MRI异常的患者中,组织学及MoAB免疫染色证实存在骨髓受累(IV期5例;III期0例;II期1例)。在其他8例MRI异常的患者中,这两种方法均未证实存在骨髓转移。5例初始MRI异常的可手术乳腺癌(II - III期)患者中有4例在随访检查中出现额外异常,并在5至18个月内出现常规临床方法可证实的转移性疾病。相反,MRI检查结果为阴性的可手术患者在3至16个月内均未出现复发性疾病(Student t检验,P = 0.01)。9例MRI正常的患者经组织学或MoAB免疫染色均无骨髓受累证据(IV期2例;III期2例;II期5例)。14例MRI异常的患者中,7例骨扫描正常,6例未显示相应异常。血清碱性磷酸酶水平升高与骨扫描异常呈直接关系,提示广泛骨受累,但与骨髓MRI阳性结果无相关性。
MRI是一种有前景的新技术,可用于检测乳腺癌患者隐匿性骨髓受累情况。II至III期疾病患者骨髓MRI异常与临床转移性疾病的早期发生之间存在良好相关性。